feedback

Faculty

Jeffrey Crawford, MD
George Barth Geller Professor for Research in Cancer
Department of Medicine
Co-Director, Solid Tumor Therapeutics Program
Duke Cancer Institute
Durham, NC

Consulting Fee: Merck, Novartis, Pfizer
Contracted Research: Amgen, AstraZeneca, Bayer, Clovis, GTx, Morphotek
Data and Safety Monitoring Board Member: Celgene, G1 Therapeutics, Janssen, Merrimack, Roche

Siwen Hu-Lieskovan, MD, PhD
Assistant Clinical Professor
Department of Medicine
Division of Hematology-Oncology
David Geffen School of Medicine at UCLA
Los Angeles, CA

Consulting Fee: Amgen, Merck
Contracted Research: Bristol-Myers Squibb, Genentech, Neon, Pfizer, Plexxikon

Antoni Ribas, MD, PhD
Professor of Medicine
Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Los Angeles, CA

Consulting Fee: Amgen, Merck, Novartis
Ownership Interest: Advaxis, CytomX, Five Prime, Kite Pharma

Reviewers:
Charles A. Butts, MD, FRCPC
Consulting Fee:  AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Pfizer
Speakers Bureau: Merck, Pfizer
Contracted Research: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, Merck, Novartis, Pfizer, Roche

Ronald A. Codario, MD, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Staff:
Vindico Medical Education Staff: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accredited By

This continuing medical education activity is provided by Vindico Medical Education.

Activity Details

Credit Type: AMA PRA Category 1 Credit
Credit Amount: 1.0
Release Date: February 24, 2017
Expiration Date: February 23, 2018
Estimated Time to Complete Activity: 1 hour
Registration Required: No
Fee for Activity: There is no fee for participating in this activity.

Activity Description

The integration of immune checkpoint inhibitors into treatment strategies for melanoma and non-small cell lung cancer (NSCLC) has dramatically improved outcomes in these patient populations. As newer immune checkpoint inhibitors progress through late-stage clinical evaluation and as treatment strategies with currently approved therapies are further defined, it is imperative for clinicians to be familiar with such treatment options and understand their mechanisms of action to facilitate effective integration into clinical practice. This activity will utilize interactive gaming technology to deliver knowledge of the basics of cancer immunotherapy, as well as to provide guidance for the optimal integration of immune checkpoint inhibitors into strategies to treat patients with melanoma or NSCLC.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Describe the role of the immune system in tumor biology and how immune checkpoint inhibitors impact disease management.
  • Implement treatment regimens that reflect the clinical safety, efficacy, and recommended usage of immune checkpoint inhibitors for the effective management of melanoma and/or NSCLC.
  • Review the clinical evidence regarding available and emerging combination immunotherapeutic strategies for the management of melanoma and/or NSCLC.

Target Audience

The intended audience for the activity is medical oncologists, pathologists, and other health care professionals interested in the use of immunotherapy in treating patients with cancer.

Requirements for Successful Completion

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Conflict of Interest Policy / Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Disclaimer Statement/ Disclosure of Unlabeled Use

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions about the Activity

Contact us at CME@VindicoCME.com

Hardware / Software Requirements

Our educational activities are available on Mac, PC, and Multi-Touch devices. For the best online experience, we recommend using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox or Safari.

Depending on your browser of choice, additional software, such as Adobe Reader®, may be required.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2017 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.